Abstract
Relapse is the major obstacle for successful transplantations in lymphoma. One of the ways to reduce relapse rates is to intensify immune-mediated effector mechanisms. Graft-versus-lymphoma may be achieved either by administration of cytokines or by allogeneic cell-mediated adoptive immunotherapy. The use of allogeneic non-myeloablative stem cell transplantation (SCT) is another option which may be applicable to all age groups. It remains to be seen whether non-myeloablative SCT will result in a lesser degree of relapse and higher disease-free survival in lymphoma patients.
MeSH terms
-
Antilymphocyte Serum
-
Bone Marrow Transplantation* / adverse effects
-
Combined Modality Therapy
-
Cytokines / adverse effects
-
Cytokines / therapeutic use*
-
Disease-Free Survival
-
Graft vs Host Disease / prevention & control
-
Hematopoietic Stem Cell Transplantation* / adverse effects
-
Humans
-
Immunosuppression Therapy
-
Immunotherapy, Adoptive*
-
Interleukin-2 / adverse effects
-
Interleukin-2 / therapeutic use
-
Lymphoma / mortality
-
Lymphoma / pathology
-
Lymphoma / therapy*
-
Neoplasm Recurrence, Local
-
Neoplasm, Residual
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Transplantation Conditioning
-
Transplantation, Autologous
-
Transplantation, Homologous / adverse effects
-
Treatment Outcome
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
Substances
-
Antilymphocyte Serum
-
Cytokines
-
Interleukin-2
-
Recombinant Proteins
-
Vidarabine
-
fludarabine